PrognosDx Licenses UCLA's Epigenetics Technology | GenomeWeb

NEW YORK (GenomeWeb News) - PrognosDx Health has signed an exclusive, worldwide license for the patent rights associated with epigenetics technology developed at the University of California, Los Angeles, the company said today.

The technology, developed by Siavash Kurdistani and David Seligson at UCLA, is based on the predictive power of global histone modification patterns and "has broad potential uses in the development of cancer prognostic assays including response predictions to therapeutics as well as research tools and reagents," PrognosDx said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.